Literature DB >> 23855304

Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease.

Jichun Yang1, Youfei Guan.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) comprises a disease spectrum ranging from simple steatosis (fatty liver) and nonalcoholic steatohepatitis to fibrosis and cirrhosis. NAFLD has become the leading cause of chronic liver diseases as well as liver-related morbidity and mortality worldwide. NAFLD is also associated with increased risk of cardiovascular diseases, hyperlipidemia, and type 2 diabetes. Insulin resistance in adipose tissues and the liver plays crucial roles in the progression of NAFLD. The family with sequence similarity 3 (FAM3) gene family is a cytokine-like gene family with four members designated FAM3A, FAM3B, FAM3C, and FAM3D, respectively. Increasing evidence suggests that the FAM3 gene family members are involved in the pathogenesis of NAFLD. In particular, FAM3B, also called pancreatic-derived factor, is an important regulator of glucose and lipid metabolism. In obesity status, increased expression and secretion of FAM3B in pancreatic islets and liver may induce lipid accumulation in the liver via the induction of hepatic insulin resistance and lipogenesis. FAM3A and FAM3D may also participate in the regulation of lipid and energy metabolism. In this brief review, we discussed the latest findings regarding the role of FAM3 gene family members, in particular FAM3B, in the pathogenesis of NAFLD.
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  FAM3 gene family; NAFLD; PANDER; steatosis

Mesh:

Substances:

Year:  2013        PMID: 23855304     DOI: 10.1111/jgh.12033

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Quantitative proteomic profiling reveals hepatic lipogenesis and liver X receptor activation in the PANDER transgenic model.

Authors:  Mark G Athanason; Whitney A Ratliff; Dale Chaput; Catherine B MarElia; Melanie N Kuehl; Stanley M Stevens; Brant R Burkhardt
Journal:  Mol Cell Endocrinol       Date:  2016-07-07       Impact factor: 4.102

2.  FAM3C activates HSF1 to suppress hepatic gluconeogenesis and attenuate hyperglycemia of type 1 diabetic mice.

Authors:  Zhenzhen Chen; Junpei Wang; Weili Yang; Ji Chen; Yuhong Meng; Biaoqi Feng; Yujing Chi; Bin Geng; Yong Zhou; Qinghua Cui; Jichun Yang
Journal:  Oncotarget       Date:  2017-11-20

3.  Circulating PANDER concentration is associated with increased HbA1c and fasting blood glucose in Type 2 diabetic subjects.

Authors:  Catherine B MarElia; Melanie N Kuehl; Tiffany A Shemwell; Amy C Alman; Brant R Burkhardt
Journal:  J Clin Transl Endocrinol       Date:  2018-02-23

4.  Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway.

Authors:  Jinmi Lee; Seok-Woo Hong; Min-Jeong Kim; Sun Joon Moon; Hyemi Kwon; Se Eun Park; Eun-Jung Rhee; Won-Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2022-02-09

5.  Enhanced glucose tolerance in pancreatic-derived factor (PANDER) knockout C57BL/6 mice.

Authors:  Shari L Moak; Grace C Dougan; Catherine B MarElia; Whitney A Danse; Amanda M Fernandez; Melanie N Kuehl; Mark G Athanason; Brant R Burkhardt
Journal:  Dis Model Mech       Date:  2014-09-12       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.